

REPLIGEN CORP  
Form 8-K  
June 28, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

---

**FORM 8-K**

---

**CURRENT REPORT PURSUANT**  
**TO SECTION 13 OR 15(D) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported) June 25, 2007

---

**REPLIGEN CORPORATION**

(Exact Name of Registrant as Specified in Its Charter)

---

**DELAWARE**

(State or Other Jurisdiction of Incorporation)

**0-14656**  
(Commission File Number)

**04-2729386**  
(IRS Employer Identification No.)

**41 Seyon Street, Building #1, Suite 100, Waltham, Massachusetts**  
(Address of Principal Executive Offices)

**02453**  
(Zip Code)

**(781) 250-0111**

(Registrant's Telephone Number, Including Area Code)

Edgar Filing: REPLIGEN CORP - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**INFORMATION TO BE INCLUDED IN THE REPORT**

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers.**

On June 25, 2007, Mr. Daniel W. Muehl, who is currently Chief Financial Officer, informed the Company that he intended to resign effective August 10, 2007 for personal reasons.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPLIGEN CORPORATION

Dated: June 28, 2007

By: /s/ Walter C. Herlihy  
Walter C. Herlihy  
President and Chief Executive Officer